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Abstract
Background: Cardiovascular diseases (CVD) are responsible for significant morbidity, premature mortality, and
economic burden. Despite established evidence that supports the use of preventive medications among patients at
high CVD risk, treatment gaps remain. Building on prior evidence and a theoretical framework, a complex intervention
has been designed to address these gaps among high-risk, under-treated patients in the Australian primary care
setting. This intervention comprises a general practice quality improvement tool incorporating clinical decision support
and audit/feedback capabilities; availability of a range of CVD polypills (fixed-dose combinations of two blood pressure
lowering agents, a statin ± aspirin) for prescription when appropriate; and access to a pharmacy-based program to
support long-term medication adherence and lifestyle modification.
Methods: Following a systematic development process, the intervention will be evaluated in a pragmatic cluster
randomized controlled trial including 70 general practices for a median period of 18 months. The 35 general practices
in the intervention group will work with a nominated partner pharmacy, whereas those in the control group will
provide usual care without access to the intervention tools. The primary outcome is the proportion of patients at high
CVD risk who were inadequately treated at baseline who achieve target blood pressure (BP) and low-density
lipoprotein cholesterol (LDL-C) levels at the study end. The outcomes will be analyzed using data from electronic
medical records, utilizing a validated extraction tool. Detailed process and economic evaluations will also be
performed.
Discussion: The study intends to establish evidence about an intervention that combines technological
innovation with team collaboration between patients, pharmacists, and general practitioners (GPs) for CVD
prevention.
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Background
Cardiovascular disease (CVD) causes significant health
burden globally. Like many other high income nations,
CVD is the leading cause of death in Australia, ac-
counting for 31 % of all deaths [1]. CVD is also respon-
sible for significant morbidity and economic burden,
emphasizing the importance of effective prevention in
primary care.
Numerous robust, large-scale clinical trials have dem-
onstrated the benefits and safety of pharmacotherapy for
CVD risk reduction. In high-risk patients, blood pres-
sure lowering [2], lipid lowering [3], and antiplatelet
therapies (in secondary prevention) [4, 5] have all been
shown to reduce the risks of CVD events. However, ap-
propriate prescribing is demonstrably suboptimal [6, 7],
with a range of patient and health system factors ad-
versely influencing long-term medication adherence [8].
A Cochrane review concluded that complex interventions
which provide education, counselling, or daily treatment
support were likely to be most effective in promoting
long-term medication adherence [9].
Previous work by The George Institute for Global
Health has developed a multifaceted quality improve-
ment intervention (HealthTracker) comprising point-of-
care computerized decision support, audit tools, and
staff training for use in the general practice setting.
HealthTracker has been described in detail elsewhere
[10], but a key component is an algorithm that extracts
data from the electronic medical record, using absolute
CVD risk estimation and the recommendations of rele-
vant guidelines to provide individualized advice on CVD
risk factor measurement and treatment. Evaluation in a
cluster randomized trial demonstrated that HealthTracker
was associated with increased CVD risk assessment and
escalation of medical therapy, with a 60 % relative im-
provement in use of optimal combination therapy among
under-treated high-risk individuals [11]. Despite these ef-
fects, substantial treatment gaps persisted.
In parallel, a range of trials have evaluated the role of
cardiovascular “polypills” (fixed-dose combinations of
blood pressure lowering drugs and statins, with or
without antiplatelet drugs) in improving adherence to
optimal preventive drug therapy among individuals at
high CVD risk. It had been posited that both prescrip-
tion of appropriate therapy and adherence to prescribed
medication would be enhanced with the availability of
such polypills because of reduced costs and simpli-
fication of complex treatment regimens. A recent meta-
analysis of three randomized controlled trials (including
one in Australian primary care) indicated that a
polypill-based strategy significantly improved medica-
tion adherence as well as reduced systolic blood
pressure (BP) and low-density lipoprotein cholesterol
(LDL-C) levels [12]. However, in all three studies, a de-
cline in medication adherence over the 12–18-month
period of observation was observed.
In many healthcare systems, including that of
Australia, pharmacists are well placed to be involved in
patient care to maintain long-term medication adher-
ence. Patients with chronic diseases visit their pharma-
cists on average twice as frequently as their general
practitioners (GPs) [13] for repeat medications, and
such visits may represent an ideal opportunity to sup-
port patients in maintaining adherence. Existing data
support the potential effectiveness of pharmacy-based
interventions, with evidence of improved medication
adherence with fee-for-service medication reviews [14],
education/counselling [15–19], and team collaboration
[15, 18, 20, 21] models. These interventions have
been implemented in the management of hyperten-
sion [16, 17, 20–23], type 2 diabetes mellitus [19],
and asthma [18].
This study aims to assess whether combining (a)
HealthTracker with (b) the availability of a range of
cardiovascular polypills and (c) a pharmacy-based ad-
herence program will improve CVD preventive medi-
cation prescribing and adherence in patients at high
absolute CVD risk. Utilizing an appropriate framework
to theorize the interaction of these combined compo-
nents, a complex intervention is being proposed. This
paper describes development of the intervention and
pragmatic cluster randomized trial that will evaluate
its clinical and cost-effectiveness, and potential scal-
ability and sustainability beyond the trial setting.
Methods/design
Description of intervention
We have used Michie’s behavior change model [24] and
process evaluations of our previous work [25–27] to de-
velop an understanding of the capabilities, opportunities,
and motivations of patients and their health providers,
as well as to theorize the expected contribution of each
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component and their interaction (e.g., polypill increases
opportunity by reducing cost and tablet burden; decision
support tools increase patient motivation and practi-
tioner capability, and individualized pharmacy support
[18] increases patient motivation). This theory-driven
approach, informed by our empirical findings, provides a
strong rationale for the multi-component intervention
and a reasonable expectation that the individual compo-
nents may potentiate one another to yield larger effect
sizes.
The intervention will involve GPs, pharmacists, and
patients (Fig. 1). GPs will have HealthTracker uploaded
on their clinical computer, linked to a server-based data
extraction tool [28] both of which integrate with their
electronic medical records (EMRs). Utilizing data within
the EMR, HealthTracker automatically calculates the ab-
solute CVD risk of a patient whose record is open or
alerts the GP if outstanding risk factors need to be mea-
sured in order to estimate risk [10]. A risk communica-
tion tool allows GPs to interact with patients about their
CVD risk and potential for altering their risk based on
beneficial or harmful changes to risk factor levels [29]. It
recommends patient-appropriate lifestyle changes with
pertinent patient resources (e.g., weight loss information
sheets, quit smoking phone apps) and prescription of
medications (including the option, where relevant, of
cardiovascular polypills) based on the simultaneous in-
terpretation of multiple clinical guidelines and given the
known characteristics of the patient. The data extraction
tool will provide GPs with collated data on their clinical
performance for key indicators and will include the cap-
acity to compare performance with other de-identified
peer practices.
HealthTracker will also provide tailored advice in rela-
tion to eight variations of a CVD polypill that are available
for this study (Table 1) through the process of over-
encapsulation. Over-encapsulation is a method of securely
enclosing solid dosage forms of medications inside a cap-
sule shell. Polypill prescriptions will be able to be filled
only at partner pharmacies. Out-of-pocket expenses for
the polypill will be incurred by participating patients
identically to those for any other drug listed on the
Pharmaceutical Benefits Scheme (PBS), which is the gov-
ernment subsidy program through which most drugs are
obtained in Australia [30]. This cost varies depending on
whether or not the patient is eligible for any concessions.
Since January 2016, the patient co-payments for non-
concession and concession card holders are $AUD38.30
and $AUD6.20, respectively [31]. The equivalent co-
payment for one medication will be charged for any poly-
pill prescription to replicate clinical practice as closely as
possible, and the participating pharmacy will retain this
fee as the cost for their dispensing services. However,
CVD polypills are not currently available on the Austra-
lian market and will not contribute towards patient safety
net entitlements [32].
Patients with any prescriptions for preventive cardiovas-
cular medications (including but not limited to a CVD
polypill) will be eligible for referral by the GP to a partner
pharmacy for potential involvement in the Pharmacy Ad-
herence Support Service (PASS). The pharmacist will
undertake initial screening with the eight-item Morisky
Medication Adherence Scale (MMAS-8) [33–35] to iden-
tify patients at moderate or high-risk of medication
non-adherence. With the aid of an electronic decision
support system, pharmacists will then use a modified
Brief Medication Questionnaire-1 (BMQ-1) to assess
reasons for non-adherence [36] and address these bar-
riers. Follow-up PASS assessments and interventions
will occur at 1, 6, and 12 months following initiation.
Fig. 1 INTEGRATE intervention
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Pharmacists will be remunerated for their time spent
with patient who participates in this program, commen-
surate with a fee structure for other services that cur-
rently generate reimbursement.
A secure electronic communication platform between
the pharmacists’ decision support tool (PASS program)
and GPs’ health records will be established to facilitate
communication between GPs and pharmacists. This will
facilitate pharmacists to send automated letters to GPs
directly from the PASS application to detail patient pro-
gress, as well as provide an opportunity for other indi-
vidualized interdisciplinary communication.
Pilot phase
Prior to large-scale implementation and evaluation of the
intervention, a pilot will be completed in at least three
general practice and pharmacy pairs for up to 8 weeks (in-
cluding a minimum of 4 weeks of follow-up after the last
patient has been included in the PASS program). Clinical
data and measures of fidelity will be collected (for ex-
ample, frequency of HealthTracker utilization). In-depth
interviews involving GPs, pharmacists, and a sample of
patients will identify barriers to the implementation of the
intervention to be addressed prior to wider application.
The pilot study will provide an initial understanding of
the operation of the study, including implementation,
mechanism of impact, and context for overall process
evaluation [37].
Trial design
The INTEGRATE study is planned as an open label,
pragmatic, cluster randomized controlled trial of 70 gen-
eral practices in Australia (Fig. 2).
Study population
General practices with EMR systems compliant with
HealthTracker use will be eligible (currently estimated as
at least 80 % of GP practices in Australia). Practices with
previous exposure to HealthTracker will be excluded.
The patient population for evaluation is based on
Australian vascular risk screening recommendations [38]
and defined as all Aboriginal and Torres Strait Islander
people ≥35 years and all others ≥45 years (no upper age
limit) who had attended the service ≥3 times in the pre-
vious 24-month period and at least once in the previous
6-month period. The outcome evaluation cohort will in-
clude patients who met these criteria at both baseline
and end of study and will be de-identified prior to data
extractions from each practice; however, an encrypted
identifier will be utilized to enable matching of the data.
Randomization
Permuted block randomization will be centrally com-
puter generated and stratified by general practice size
(<500 patients vs ≥500 patients) and location
Table 1 CVD polypills for use in the INTEGRATE study
Tablet name ACEI/ARB Second antihypertensive agent Statin Antiplatelet agent
“Polypill Perindap Asp” Perindopril erbumine (4 mg) Indapamide (1.25 mg) Rosuvastatin (10 mg) Aspirin (100 mg)
“Polypill Perindap” Perindopril erbumine (4 mg) Indapamide (1.25 mg) Rosuvastatin (10 mg) –
“Polypill Hydrotelmi Asp” Telmisartan (40 mg) Hydrochlorothiazide (12.5 mg) Rosuvastatin (10 mg) Aspirin (100 mg)
“Polypill Hydrotelmi” Telmisartan (40 mg) Hydrochlorothiazide (12.5 mg) Rosuvastatin (10 mg) –
“Polypill Peramlo Asp” Perindopril erbumine (4 mg) Amlodipine (5 mg) Rosuvastatin (10 mg) Aspirin (100 mg)
“Polypill Peramlo” Perindopril erbumine (4 mg) Amlodipine (5 mg) Rosuvastatin (10 mg) –
“Polypill Amtelmi Asp” Telmisartan (40 mg) Amlodipine (5 mg) Rosuvastatin (10 mg) Aspirin (100 mg)
“Polypill Amtelmi” Telmisartan (40 mg) Amlodipine (5 mg) Rosuvastatin (10 mg) –
ACEI angiotensin converting enzyme inhibitor, ARB angiotensin receptor blocker
Fig. 2 INTEGRATE study outline
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(metropolitan vs non-metropolitan by rural, remote, and
metropolitan Area (RRMA) classification [39]).
Post-randomization phase
Those practices randomized to the intervention will have
HealthTracker installed in all clinical computers, and the
staff will be provided training in its use. Each practice
will be paired with a partner pharmacy that uses elec-
tronic dispensing software and is willing to dispense the
polypill and deliver the PASS program. Brief education
will also be provided to the GP about the availability and
use of polypill therapy and to the pharmacist in delivery
of the PASS program. Pharmacies will be assisted in es-
tablishing systems to stock and re-order supplies of the
polypills. Once the training is delivered and the inter-
vention is commenced, there will be minimal involve-
ment of study staff, other than through a Help Desk
support function. The general practices assigned to usual
care will not be paired to partner pharmacies nor have
access to HealthTracker, polypill prescribing or PASS
program referrals.
Outcomes
The primary effectiveness outcome is the proportion of
patients at high CVD risk who were not on full preventive
treatment at baseline (“under-treated”) who achieve rec-
ommended target BP and LDL-C levels at study end. High
CVD risk is defined by current Australian guidelines as
those with a history of established CVD, presence of high-
risk conditions (diabetes and age over 60 years, diabetes
and albuminuria, stage 3B chronic kidney disease, systolic
BP ≥180 mmHg, diastolic BP ≥110 mmHg, or total chol-
esterol >7.5 mmol/L), or a calculated 5-year CVD risk of
>15 % using the 1991 Anderson Framingham equation
[38]. Full preventive treatment is defined as a combination
of antiplatelet drug, at least one blood pressure lowering
medication and a statin in those with established athe-
rothrombotic CVD, and the combination of at least one
blood pressure lowering medication and a statin in all
other high-risk patients. Target levels are defined as BP
≤140/90 mmHg or ≤130/80 mmHg in people with dia-
betes or albuminuria, and LDL-C <2.0 mmol/L.
Secondary effectiveness outcomes include the propor-
tion of under-treated high CVD risk patients at baseline
achieving recommended target BP at end of study; the
proportion of under-treated high CVD risk patients at
baseline achieving recommended target LDL-C at end of
study; the proportion of all high CVD risk patients
achieving BP and LDL-C targets at end of study; the
proportion of patients achieving BP and LDL-C targets
and prescribed antiplatelet agent (if relevant) at end of
study; recording of risk factor measurement and mean
levels during the study period; treatment intensification
in high risk-patients; and the proportions of non-high
CVD risk patients receiving BP lowering, statin, and an-
tiplatelet therapy at the end of the study.
Seventy general practices with a mean patient cluster
size of 60 will provide at least 80 % power (2α = 0.05) to
detect a relative risk of ≥1.35 in the proportion of high
CVD risk patients achieving BP and LDL-C targets be-
tween the intervention and control arms. This is based
on the assumptions of an intraclass correlation coeffi-
cient of 0.01 (from a previous trial of HealthTracker)
and that 10 % of relevant patients in the usual care arm
will have BP and LDL-C levels at or below target by the
study end.
Individual patient data will be analyzed on an intention-
to-treat basis using Gaussian and log-binomial generalized
estimating equation regressions for continuous and binary
outcomes, respectively, and will account for clustering of
patients within practices. Pre-specified subgroup analyses
will also be performed using the randomization strata.
Economic and process evaluation
An economic evaluation of INTEGRATE will be con-
ducted to estimate the incremental costs and benefits of
the intervention to the health system. This evaluation
will comprise a trial-based component as well as a mod-
elled evaluation of the long-term costs and outcomes.
Cost estimates will be based on all aspects of the inter-
vention, including direct medical utilization costs (e.g.,
general practitioner consultations, pathology obtained
from the data extraction tools and valued at prevailing
costs) and intervention costs (e.g., training, tablet de-
vices, software, and IT support, practice implementation
costs). The incremental cost-effectiveness of the inter-
vention in achieving each of the study outcomes will
then be estimated. To understand the cost-effectiveness
of INTEGRATE beyond the trial setting, a Markov
model will be used to predict the long-term intervention
effects and costs. The model will be based on tracking
the progression of a cohort of surviving patients at the
end of the trial over decades in which they potentially
progress, based on annual cycles, through a number of
health states including no disease, death, myocardial in-
farction, and stroke. Patients in the intervention group will
be tracked separately from those in the usual care group.
We will draw on published evidence to determine the
transition probabilities between health states, costs associ-
ated with CVD events, and quality of life. Incremental
cost-effectiveness ratio will be estimated by folding back
the model at a point in time in the future in which pa-
tients in both groups have all died and the difference in
accumulated quality-adjusted life-years (QALYs) and costs
will be estimated (discounted at an appropriate rate).
These analyses will provide information on the investment
case for INTEGRATE, with appropriate sensitivity analysis
to account for variations that may occur across different
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settings and thus address issues of generalizability and
scalability.
A detailed process evaluation will be crucial in the inter-
pretation of the effectiveness findings. This will assess
whether INTEGRATE was delivered as planned (fidelity,
dose, and reach), the mechanisms by which the study out-
comes were achieved (or not achieved) and how context-
ual factors impacted on the findings [37]. A logic model
[40] (Fig. 3) will be used to evaluate the feasibility of
upscaling and the potential application of INTEGRATE to
different “real life” settings. The process evaluation will in-
volve mixed methods evaluation including quantitative
data collection on the usage of the different components
of the study and semi-structured interviews with patients,
pharmacists, and GPs. The interviews will provide infor-
mation on the experiences and perspectives of patients
and health care providers with purposive sampling to en-
sure diverse opinions are gained from groups with high
and low uptake of the intervention and will continue until
thematic saturation is achieved.
Ethical considerations
INTEGRATE has been approved by the University of
Sydney Human Research Ethics Committee (HREC)
and ratified by the corresponding ethics committees at
Monash University and the University of Notre Dame.
Only de-identified patient data will be collected for the
purpose of the study and will be securely stored at The
George Institute. Written informed consent will be ob-
tained from all patients who are prescribed the polypill
or who participate in the PASS program, as well as
from all patients, pharmacists, and GPs who participate
in the interviews for the process evaluation.
Timelines
The pilot development phase will be implemented from the
second quarter of 2016. INTEGRATE will subsequently
begin with pre-randomization baseline data extraction
followed by trial implementation in the third quarter of
2016 and will conclude in the first quarter of 2019, followed
by data analysis and dissemination of results.
Discussion
Many CVD deaths are preventable with lifestyle mea-
sures and medication management. Yet, despite effica-
cious treatments being available, significant morbidity
and premature mortality persist; therefore, this study
aims to trial a systems approach to the ongoing burden
Fig. 3 INTEGRATE logic model
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of CVD. As well as population-based approaches, atten-
tion needs to be focused on the large numbers of high-
risk, under-treated patient populations for maximum
public health benefit. The primary care setting is ideal
for these preventative interventions due to the high fre-
quency of patient encounters, with 83 % of Australians
attending a GP every year [41].
The INTEGRATE intervention aims to simultaneously
address a number of steps in health professional and pa-
tient interactions that may lead to suboptimal care or
provide opportunities for improved care. These steps
include risk factor measurements (such as BP, LDL-C),
estimation of absolute CVD risk, risk communication,
appropriate treatment recommendations (including life-
style counselling) and prescriptions, patient education,
addressing barriers to adherence, and facilitating inter-
disciplinary communication between GPs and pharma-
cists. While there is growing evidence that a variety of
isolated interventions such as electronic decision sup-
port can aid this process, INTEGRATE aims to provide
evidence of the potentially synergistic effectiveness of a
model of care combining technological innovation with
team collaboration between pharmacists and GPs. In the
Australian context, this is consistent with the new “med-
ical home” model of patient-centered care involving con-
tinuity of care with interdisciplinary collaboration, as
well as the need for ongoing quality improvement to en-
hance systems of healthcare delivery [42].
Some potential limitation should be acknowledged.
Polypills are not available for prescription in Australia,
and despite using the process of over-encapsulation of
marketed generic drugs, these are considered unapproved
therapeutic agents from a regulatory perspective, and
written informed consent is required from patients for
prescription of polypills as part of this study. The INTE-
GRATE intervention has been carefully designed to
minimize disruption to workflow for participating GPs in
particular; however, this required trial process has the po-
tential to significantly undermine this principle. Conse-
quently, polypill use in the trial may not reflect likely use
in “real world” practice and may lead to under-estimation
of the overall effectiveness of the overall intervention.
While unlikely in the context of a cluster randomized trial
with geographically dispersed practice-pharmacy pairs, it
is possible that a control group patient may attend a phar-
macy in the intervention group. Training of pharmacists
will include reminding pharmacists to restrict the PASS
program to patients from GP practices randomized to the
intervention.
The ongoing process of refining the INTEGRATE
intervention will be highly influenced by local context.
While the process evaluation will attempt to define
features of the context that might help explain who it
works best for and under which conditions, this will
almost certainly limit direct extrapolation of the effect-
iveness findings from the trial to other settings with dif-
ferent health care systems. Nevertheless, efforts to
understand the effects of “function over form” through
the process evaluation may help inform potential adap-
tion to other health systems.
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